Kabihep

Heparin inhibits the clotting of blood and the formation of fibrin clots both in vitro and in vivo. In combination with a co-factor, it inactivates thrombin thus preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Heparin Sodium inhibits reactions which lead to clotting but does not alter the normal components of the blood. Although clotting time is prolonged by therapeutic doses, bleeding time is usually unaffected. Heparin Sodium does not have flbrinolytic activity, therefore it will not lyse existing clots.

Although dosage must be adjusted for the individual patient based upon suitable laboratory  tests,  the following  may  be used  as  guidelines for achieving therapeutic anticoagurant effect with heparin:

By deep subcutaneous (Intrafat) or, if necessary, intramuscular injection: After an initial IV injection, inject 10,000 to 20,000 units of a concentrated  heparin   sodium   solution   subcutaneously   followed by 8,000 to 10,000 units subcutaneously eight hours, or 15,000  to 20,000 units every twelve hours.

By Intermittent Intravenous Injection: 10,000 units initially, then 5,000 to 10,000  units  every  four  to  six  hours.  These  amounts  may be given either undiluted or diluted with 50 to 100  ml  of  isotonic sodium chloride injection.

By continuous intravenous infusion: Add 20,000 to 40,000 units of heparin sodium to 1,000 ml of the solution for infusion. For most patients, the rate of flow should be adjusted to deliver  approximately 20,000 to 40,000 units in 24 hours.

For Anticoagulant therapy in Prophylaxis & Treatment in Venous Thrombosis & its extension;

For prophylaxis and treatment of pulmonary embolism;

In Atrial fibrillation with Embolization;

For Diagnosis and treatment of Chronic consumptive coagulopathies;

For prevention of clotting in arterial and heart surgery;

For prevention of cerebral thrombosis in evolving stroke;

As an adjunct in treatment of coronary occlusion with acute myocardial infarction;

As an adjunct in prophylaxis and treatment of peripheral arterial embolism;

As a general anticoagulant in

• Blood Transfusions
• Extra Corporeal Circulation
• Dialysis procedures and
• Blood samples for Laboratory purposes.

PACKING & PRESENTATION

5 ml Vials of 25,000 units                           - 5000 IU/ml

5 ml Vials of 5,000 units                             - 1000 IU/ml